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The overgrowth disorder BeckwitheWiedemann syndrome (BWS) is associated with dysregulation of
imprinted genes at chromosome 11p15.5. The molecular defects are heterogeneous but most of the cases
are associated with defective DNA methylation at either one of two Imprinting Control Regions (IC1 and
IC2) or Uniparental paternal Disomy (UPD) at 11p15.5. In rare cases, the BWS phenotype has been found
associated with maternal transmission of IC1 microdeletions. We describe a family with a novel 1.8 kb
deletion that is associated with hypermethylation at IC1. The mutation results from recombination
between highly homologous sequences containing target sites for the zinc-ﬁnger protein CTCF (CTSs).
This ﬁnding supports the hypothesis that the function of IC1 and the penetrance of the clinical pheno-
type depend on the spacing of the CTSs resulting from recombination in the mutant allele.
 2011 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
The BeckwitheWiedemann syndrome (BWS, OMIM 130650) is
a congenital overgrowth disorder associated with dysregulation of
imprinted genes located at chromosome 11p15.5 [1]. Children
affected by BWS show with variable expressivity several charac-
teristic features, including macroglossia, gigantism, abdominal wall
defects and embryonal tumors, particularly Wilms tumor. The
11p15.5 imprinted gene cluster includes more than ten imprinted
genes organized in two domains, each controlled by a separate
imprinting centre region (IC1 and IC2, ref. [2]). The IGF2 and H19
genes are in the telomeric domain, and genes such as CDKN1C and
KCNQ1OT1 are in the centromeric domain. Individuals with BWS
have heterogeneous molecular defects affecting one or both
domains of the cluster, including paternal uniparental disomy
(UPD) or duplication, CDKN1C mutations and IC epimutations and
microdeletions. BWS cases with alterations in the telomeric domain
or UPD have a higher risk of developing Wilms tumor than cases
with other molecular abnormalities.
The imprinting of the paternally expressed IGF2 and maternally
expressed H19 genes is controlled by IC1, which is located upstreammental Science, University of
.
er CC BY-NC-ND license.of the H19 transcription start site. On the maternal chromosome,
IC1 binds the zinc ﬁnger protein CTCF that, by inducing higher
order chromatin structures, insulates IGF2 from the effects of
downstream enhancers [3]. On the paternal chromosome, the
insulator function of IC1 is inactivated by DNA methylation that
inhibits CTCF binding. In BWS, aberrant IGF2 activation and H19
silencing result from gain of DNA methylation at the maternal IC1.
In contrast, IGF2 silencing and H19 activation are associated with
loss of DNA methylation at the paternal IC1, in the growth-
deﬁciency disorder, SilvereRussell syndrome (SRS, ref. [4]).
In the majority of BWS and SRS cases, the IC epimution is not
linkedwith sequence changes of the region, but in a few individuals
the DNA methylation defect is associated with in cis mutations [1].
In particular, microdeletions in the IC1 sequence abolishing 1e3
CTCF-target sites (CTS) have been described in BWS cases [5e7].
The clinical phenotype associated with these mutations, however,
is not uniform and we have previously proposed that a critical
factor may be the spacing of the remaining CTSs in the mutant
allele [8].
Here we report a familial case of BWS with a novel IC1 micro-
deletion. The deletion is similar in size to previously reported ones,
but removes different sets of CTSs. When maternally transmitted, it
is associated with IC1 hypermethylation and BWS phenotype.
Overall, the results are consistent with the hypothesis that the
spatial organization of the CTSs is critical for the function of the
imprinting regulatory element and that internal deletions resulting
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and fully penetrant clinical phenotype.2. Materials and methods
2.1. Case report
The propositus was born to unrelated parents after 37 weeks
gestation and a pregnancy characterized by polyhydramnios. Birth
weight was 5080 g (>95th centile), length was 59 cm (>95th
centile), and OFC was 36.1 cm (75th centile). The presence of
macrosomia, macroglossia, ear pits, neonatal hypoglycaemia,
rectum diastasis, umbilical hernia, hepatomegaly, nephromegaly
and ureteral abnormalities were consistent with the clinical diag-
nosis of BWS. Echocardiographic examination revealed the pres-
ence of patent foramen ovale. Feeding difﬁculties were observed
during infancy. The propositus’ mother was a 29 year-old woman,
at the time of delivery. At birth, she was macrosomic (birth weight
5400 g), displayed macroglossia and was affected by kidney disease
(renal congenital renal cysts and kidney stones). No signs typical of
BWS were evident in the other family members (Fig. 1).
All the genetic analyses were performed with the informed
consent of the parents of the family members.2.2. PCR and DNA sequencing
PCR ampliﬁcation of the IC1 regionwas obtained from leukocyte
DNA by using the primers: 50-CGCTGTGGCTGATGTGTAGTAGAG-30
and 50-CATTTCCGTCTCCACAGCCACAAC-30 and the Taq BIO-X-ACT
Long (BIOLINE) as described [5]. The fragments generated from
the allele carrying the microdeletion were gel-puriﬁed and clonedFig. 1. Pedigree of the familial BWS case and segregation of chromosome 11p15.5
genotypes. The genotypes for the microsatellite markers TH, D11S922 and D11S4046
are shown in descending order; the haplotype cosegregating with the BWS phenotype
is red colored.onto pCR II (Invitrogen). DNA sequencing was obtained from
PRIMM (Italy).
2.3. Microsatellite analyses
11p15 microsatellite markers TH, D11S4046 and D11S922 were
ampliﬁed using FAM-labeled and HEX-labeled primers and detec-
ted using an ABI 3100 capillary electrophoresis instrument. Data
were analysed using GeneMapper Software. Primers and PCR
conditions for the microsatellite markers were obtained from the
NCBI UniSTS Database (http://www.ncbi.nlm.nih.gov/sites/entrez?
db¼unists).
2.4. DNA methylation analysis
The level of DNAmethylation at IC1 (CTS1 and CTS6 regions) and
IC2 was determined by COBRA, as previously described [7]. The
allele-speciﬁc DNA methylation proﬁle of CTS2 was determined by
bisulﬁte genomic sequencing. DNA was treated with sodium
bisulﬁte using EpiTect bisulﬁte kit (Qiagen) and PCR ampliﬁed with
the following primer pairs:
In the individuals carrying the 1.8 kb B5-B2 deletion: CTS2_F 50-
AGGTGTTTTAGTTTTTTGGATGATA-30 with CTS2Δ_R 50-CTCCAAAAA
TACACATATACTATACAAAAAC-30 for the deleted allele and CTS2_F
50-AGGTGTTTTAGTTTTTTGGATGATA-30 with CTS2_R 50-CAATTTCT
ATACCTACCAAAAACC-30 for the wild-type allele. Annealing
temperatures were 60 C with 1.5 mM of MgCl2).
In the individual carrying the 1.4 kb B5-B3 deletion: CTS2_F 50-
AGGTGTTTTAGTTTTTTGGATGATA-30 with CTS2Δ_R2 50-TAAATAT
CCTATCCCTAATAAC-30 for the deleted allele (annealing tempera-
ture was 52 C with 1.5 mM of MgCl2) and CTS2_F 50-AGGTGTTT-
TAGTTTTTTGGATGATA-30 with CTS2_R2 50-CACCTAACTTAAATAACC
CAAAAC-30 for the wild-type allele (annealing temperature was
60 C with 2.0 mM of MgCl2). The PCR products were gel-puriﬁed
using QIAquick gel extraction (Qiagen), then cloned in Topo pCRII
vector (Invitrogen) and individual clones sequenced by PRIMM
(Italy).
3. Results
The propositus, his unaffected brother and their parents were
analysed for the presence of DNA methylation defects at 11p15.5.
The results obtained by COBRA demonstrated abnormal DNA
methylation at IC1 and normal DNA methylation at IC2 in II2 and
III1. In particular, two CTCF-target sites (CTS1 and CTS6) in the IC1
region were found hypermethylated when compared to controls
(Table 1). Normal methylation was detected in the other family
members.
We previously demonstrated that a subset of BWS patients with
IC1 hypermethylation carry microdeletions in this regulatoryTable 1
Methylation-values at IC1 and IC2 in the family.
Individual IC1 IC2
CTS1 CTS6
II-2 7.1 4.3 1
II-3 1 1 1
III-1 10.2 3.4 1
III-2 1 1 1
NCa 1 0.36 1 0.21 1 0.19
Numbers represent me/unme ratios at ICs, as determined by COBRA. The ratios were
normalised against the average values of 50 control samples. Numbers greater than
1 indicate gain of methylation.
a NC, normal controls.
Fig. 2. Map of the IC1 deletions. The human IC1 is organized in two large repetitive units each consisting of A- and B-type repeats. The positions of the CTCF target sites (CTSs), OCT-
binding sites and H19 transcription start site are indicated. The extensions of the previously described deletions [5e7] are indicated by black bars, while the new case is in red. The
OCT-binding site 1 was found mutated in BWS [11]. Note that the CTSs 2e3 are abolished in the Δ1.8 B6-B3 deletions, CTS4 in the Δ1.4 B5-B3 deletion and CTSs 3e5 in the Δ2.2 B5-B1
deletion, while CTSs 3e4 are lost in the novel Δ1.8 B5-B2.
A. De Crescenzo et al. / European Journal of Medical Genetics 54 (2011) e451ee454 e453region [5,7]. We looked for the presence of IC1 microdeletions in
this family. DNA puriﬁed from blood leukocytes of all family
members was analysed by long-range PCR. A fragment carrying
a 1.8 kb deletionwas ampliﬁed in individuals II2 and III1, while only
a PCR product of normal length was obtained from the other family
members. The deletion breakpoints were identiﬁed by sequencing
the PCR products and found to be located between at
chr11:2021870 and chr11:2023704 (NCBI37/hg19).
The human IC1 is organized into two large repeated units, each
composed of a 450 bp A-type repeat and several highly homolo-
gous 400 bp B-type repeats containing target sites for CTCF (CTS,
see Fig. 2). The novel 1.8 kb deletion eliminates most of the B5
repeat together with the entire A2, B4, B3 and a small part of the B2
repeat. Although the deletion has the same width of previously
reported ones, it involves different B-repeats and CTSs. Indeed, the
three previously reported 1.8 kb deletions abolish CTSs 2 and 3,
while the novel deletion removes CTSs 3 and 4.
In II2 the IC1microdeletion originated de novo. To determine the
parental origin of the chromosome carrying the deletion in II2, we
analysed the segregation of the 11p15 haplotype in the family, by
typing for three microsatellite markers (Fig. 1). The results showed
that II2 and III1 inherited maternally the same 11p15 haplotype
and that this was not shared by the unaffected II1 and III2, indi-
cating that II2, as well as III1, carries the IC1 microdeletion on her
maternal chromosome. Affected and unaffected individuals
showed normal allelic balance at 11p15.5.
To further study the effect of the microdeletion on IC1 methyl-
ation, we determined separately the methylation status of the
maternal and paternal IC1 alleles by bisulﬁte sequencing in II2 and
III1. For this purpose, we took advantage of the deletion and usedFig. 3. DNA methylation proﬁle of CTS2 in II2 and a control individual, as determined by b
cloned; each circle corresponds to a CpG dinucleotide. Filled circles designate methylated
indicated. The individual analysed as control carries a 1.4 kb B5-B3 deletion on its paternalallele-speciﬁc primers to amplify selectively the maternal and
paternal CTS2 sequence. As a control, we performed a similar
analysis in an individual with normal phenotype previously shown
to carry a 1.4 kb B5-B3 deletion on his paternal chromosome [7].
The results demonstrated that both the paternal and the maternal
IC1 alleles were methylated in II2 and III1 while the paternal allele
only was methylated in the control (Fig. 3 and data not shown).
4. Discussion
Familial BWS cases are rare. This study reports a novel micro-
deletion of the IC1 region segregating with disease in a parent of
origin-dependent dominant manner. The deletion abolishes two
out of the seven CTCF target sites (CTSs) and its maternal trans-
mission is associated with hypermethylation of the residual IC1
sequence and the BWS phenotype.
In the wildtype IC1, the CTSs are arranged in two large repetitive
units of three sites each, separated by about 1000 kb. The mutation
described in this study further expands the list of molecular defects
derived from recombination between repeats of the IC1 region,
including both microdeletions and microduplications [9,10].
Comparison with previously reported IC1 mutations supports the
hypothesis that the correct spacing rather than the number or the
type of CTSs is critical for IC1 function. Indeed, in the alleles
carrying the microdeletions, the spacing between the CTSs changes
and the two cluster of sites merge as a consequence of recombi-
nation between the repeats (Suppl. Fig. 1). We observe that the
cases inwhich clusters of 4e5 CTSs are generated (6 mutations) are
all associated with hypermethylation of the maternal IC1, while
differential methylation is maintained in a case in which a longerisulﬁte genomic sequencing. Each line corresponds to a single template DNA molecule
cytosine; open circles, unmethylated cytosines. The CpGs included in the CTS2 are
chromosome. Results very similar to II2 were obtained from III1 (not shown).
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resembling those of the two large wild-type units.
The mechanism by which some of the microdeletions result in
gain of methylation of the residual IC1 sequence is unknown. Point
mutations found in a couple of BWS cases implicate an OCT1/OCT4
binding site in the control of IC1methylation [11]. However, the loss
of this site does not correlate with the DNA methylation status of
the deleted alleles (Fig. 2). An alternative hypothesis is that the
binding of CTCF to DNA depends on the spacing of the CTSs and that
this protein binds the long clusters of the D1.4e1.8 kb alleles less
efﬁciently than the wild-type and the D2.2 kb alleles. CTS mutation
results in hypermethylation of the H19 IC in the mouse, indicating
that CTCF binding is required to maintain the insulator element
hypomethylated and functional on the maternal chromosome [2].
The IC1 methylation status is also relevant for the clinical pheno-
type. Indeed, an incompletely penetrant BWS phenotype was
reported for the 2.2 kb deletion that maintains the normal differ-
ential methylation of the maternal IC1 [6]. In contrast, this study
demonstrated that the 1.4e1.8 kb deletions always result in IC1
hypermethylation and BWS phenotype with complete penetrance.
Pre-natal genetic testing should be considered for such families, as
the recurrence risk may be as high as 50% upon maternal
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